Zymeworks Inc news

• Plan ensures shareholders are protected and treated equitably
• Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders

VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Jun. 10, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the “Board&